News und Analysen
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
EQS-News: ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
EQS-News: ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will host today an R&D event for investors
Sensorion to Participate in Various Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Sensorion Reports 2022 First Half Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
POXEL SA (Euronext : POXEL - FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
BIOCORP gibt anlässlich der EASD-Jahrestagung die CE-Kennzeichnung von SoloSmart® bekannt, einem medizinischen Hilfsmittel für SANOFI Solostar®-Pens
fcAufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA‐PME-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced
DGAP-News: Abivax presents first-half 2022 financial results and operations update
Valbiotis informiert über seine Fortschritte und veröffentlicht seinen Finanzbericht für das erste Halbjahr 2022
Valbiotis (FR0013254851 – ALVAL/PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
Regulatory News:
Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces positive confirmatory data
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website